Premas Biotech announced that its joint venture Oravax will initiate testing of their oral virus-like particle (VLP) vaccine candidate against Omicron variant of SARS-CoV 2 virus through preclinical, in vitro and challenge studies to assess its efficacy for the new mutant strain. Premas Biotech, Oramed Pharmaceuticals, MyMD Pharmaceuticals, and certain other shareholders formed Oravax Medical to bring an oral COVID-19 vaccine to the market.
- Read more about Premas Biotech and Oravax Medical to Test Their Triple Antigen Oral Vaccine Candidate Against Omicron
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/premas-biotech-and-oravax-medical-to-test-their-triple-antigen-oral-vaccine-candidate-against-omicron
No comments:
Post a Comment